Please login to the form below

Not currently logged in
Email:
Password:

BRVO

This page shows the latest BRVO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

BRVO, one of the two main types of retinal vein occlusion, is caused by blood clots in a branch of the main vein in the retina, leading to blood and fluid ... If left untreated, BRVO can significantly impact a person's vision. Within the next three

Latest news

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    Lilly says that, although 2011 and 2013 NICE guidance backs laser photocoagulation as a first-line treatment of visual impairment due to BRVO, clinical practice has since changed. ... NICE's next appraisal committee meeting on Eylea  and its use in

  • Bayer's Eylea cleared for wider use in Europe Bayer's Eylea cleared for wider use in Europe

    macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common

  • Germany's IQWiG delivers bad news for Bayer’s Eylea Germany's IQWiG delivers bad news for Bayer’s Eylea

    Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause

  • Bayer files eye drug Eylea for new use in EU Bayer files eye drug Eylea for new use in EU

    retinal vein occlusion (BRVO), a common cause of visual impairment in the elderly. ... BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved.

  • NICE backs new use for Bayer’s Eylea NICE backs new use for Bayer’s Eylea

    Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

WHITE PAPER 05: Improving the effectiveness of clinical trial recruitment materials
With exclusive research conducted by COUCH Health, gain insight into clinical trial recruitment materials best practice....
COVID-19: the race to find a vaccine
How biopharma is working to bring an end to the pandemic...
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Global product lead George Kirk hails the triumph of selumetinib, which has just won FDA approval...

Infographics